RCKT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Rocket Pharmaceuticals Inc (RCKT) is not a strong buy for a beginner, long-term investor at this time. The stock lacks positive momentum, has weak financial performance, and no significant catalysts or trading signals to support a bullish outlook. A hold is recommended until more favorable conditions arise.
The MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 35.674, and moving averages are converging, showing no clear trend. The stock is trading near its S1 support level of 4.304, with resistance at 5.289.
NULL identified. No recent news or significant insider or hedge fund activity. Analysts have mixed views, with some raising price targets but maintaining cautious ratings.
Financial performance is weak, with a significant YoY drop in net income (-29.49%) and EPS (-38.71%). The stock has no recent AI Stock Picker or SwingMax trading signals. Analysts' ratings include a Sell from Goldman Sachs and an Equal Weight from Morgan Stanley.
In Q4 2025, the company reported no revenue growth (0.00% YoY), a net income loss of -$42.54M (-29.49% YoY), and a significant EPS drop to -0.38 (-38.71% YoY). Gross margin remains at 0.
Goldman Sachs maintains a Sell rating with a price target of $3, while Cantor Fitzgerald raised its price target to $10 with an Overweight rating. Morgan Stanley lowered its price target to $5 with an Equal Weight rating, reflecting mixed sentiment.
